FIELD: pharmaceutics. SUBSTANCE: composition is necessary for immunosuppressive therapy. The composition includes 2-amino-2-[2- (4-octylphenyl)ethyl] -propane-1,3-diol or its pharmaceutically acceptable acidic-additive salt as an active ingredient and lecithin at the ratio of 5- 300 weight portion per 1 weight portion of active ingredient. Composition could additionally contain a saccharide and could be prepared in the form of liquid preparation. Composition is used to suppress the detachment at transplantation of an organ or bone marrow, conduct maintaining immunosuppressive therapy, treat autoimmune and allergic diseases and to decrease local inflammation. EFFECT: higher efficiency. 11 cl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS | 1999 |
|
RU2204387C2 |
| PREPARATION FOR TOPICAL USE FOR IMMUNOSUPPRESSION AND TREATMENT OF AUTOIMMUNE AND ALLERGIC DISEASES | 1996 |
|
RU2156127C2 |
| PHARMACEUTICAL COMPOSITION EXHIBITING IMPROVED FLOWABILITY, DRUG PREPARATION, METHOD FOR PREPARING AND USING | 2012 |
|
RU2496486C1 |
| 2-AMINO-1,3-PROPANEDIOL COMPOSITIONS | 2005 |
|
RU2402324C2 |
| COMPOSITIONS, BASED ON 2-AMINO-1,3-RPOPANEDIOL COMPOUNDS | 2010 |
|
RU2468793C2 |
| 2-AMINOPROPANE-1,3-DIOL DERIVATIVE, ITS PHARMACEUTICAL APPLICATION AND INTERMEDIATE SUBSTANCES FOR THEIR SYNTHESIS | 1998 |
|
RU2198162C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
| PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATMENT OF DEMYELINATING DISEASES (VERSIONS) AND METHOD OF ITS OBTAINING | 2012 |
|
RU2482842C1 |
| INHALATION FATTY EMULSION | 1999 |
|
RU2212230C2 |
| AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 2008 |
|
RU2453532C2 |
